Enclomiphene Citrate vs AndroGel: Real-World Evidence Comparison

What Each Drug Actually Does

Enclomiphene and AndroGel solve the same problem through opposite mechanisms. Enclomiphene blocks estrogen receptors in the hypothalamus, removing negative feedback and driving a rise in endogenous LH and FSH. AndroGel bypasses the entire hormonal axis and delivers testosterone directly through the skin. That single mechanistic difference explains nearly every downstream advantage and disadvantage each drug carries.

Enclomiphene Citrate: Mechanism and Pharmacology

Enclomiphene is the trans-isomer of clomiphene. Unlike the racemic clomiphene citrate (Clomid), which contains both the active trans-enclomiphene and the longer-acting zuclomiphene isomer, purified enclomiphene clears the body within 24 hours. That shorter half-life reduces the visual disturbances and mood effects sometimes attributed to accumulated zuclomiphene. Typical dosing studied in trials ranges from 12.5 mg to 25 mg taken orally each morning.

Because LH and FSH both rise, the Leydig cells and Sertoli cells remain active. Testicular volume stays stable. Sperm concentration either holds steady or increases, which is a meaningful difference from every form of exogenous testosterone. The Endocrine Society's 2018 clinical practice guideline explicitly states that testosterone therapy is "relatively contraindicated" in men who want to preserve fertility, making SERM-based therapy the preferred starting point in that group.

AndroGel: Mechanism and Pharmacology

AndroGel 1% (testosterone gel) delivers testosterone transdermally, bypassing hepatic first-pass metabolism. A standard starting dose of 5 g applied once daily to the shoulders or upper arms produces serum total testosterone levels in the normal male range for most patients within two weeks. The FDA-approved labeling for AndroGel 1% specifies a target range of 400 to 700 ng/dL and requires dose adjustment based on morning serum T measured 14 days after initiation or dose change.

The gel suppresses LH to near-undetectable levels within days. Testicular size decreases over months. Sperm output drops to near-zero within 3 to 6 months in most men, consistent with its off-label use as a male contraceptive in research settings. A Cochrane review of testosterone-based male contraception confirmed azoospermia or severe oligospermia rates exceeding 80% in men using exogenous T for 6+ months.

Real-World Evidence: What the Numbers Show

Kim et al. 2016 (Enclomiphene)

The most-cited controlled comparison of enclomiphene versus topical testosterone in men with secondary hypogonadism is the Phase III study by Kim and colleagues, published in BJU International. In that trial (N=12 weeks, multiple-dose arms), enclomiphene 12.5 mg and 25 mg daily both normalized serum testosterone while simultaneously raising LH and FSH, whereas topical testosterone normalized T but suppressed LH and FSH below baseline. At the 12-week endpoint, the 25 mg enclomiphene arm produced a mean total T of approximately 570 ng/dL with LH and FSH values above 3 IU/L, confirming intact HPG axis function throughout treatment.

The study also examined a critical real-world scenario: what happens after stopping therapy. Men who discontinued topical testosterone saw T fall back to hypogonadal levels within weeks, and their LH/FSH remained suppressed for an additional 4 to 8 weeks, indicating prolonged HPG axis suppression. Men who stopped enclomiphene recovered to baseline T levels but without the same degree of axis suppression, suggesting a faster hormonal rebound. That recovery pattern supports enclomiphene as a reversible, fertility-compatible option.

The T-Trials (AndroGel, N=788)

The Testosterone Trials, a coordinated set of seven double-blind, placebo-controlled trials, represent the most rigorous real-world evidence base for AndroGel in older men with low testosterone. In NEJM 2016, Snyder et al. Reported that AndroGel 1% (dose-adjusted to maintain T at 500 to 1000 ng/dL) significantly improved sexual activity, sexual desire, and erectile function scores compared to placebo over 12 months (P<0.001 for sexual function composite).

Bone mineral density at the spine and hip also improved significantly in the bone sub-trial, and walking distance improved modestly in the physical function sub-trial, though the latter did not reach the pre-specified clinical threshold of 50-meter improvement. Cognitive function, as measured in a separate cognitive sub-trial, did not improve with AndroGel relative to placebo. These data paint a nuanced picture: AndroGel reliably improves sexual function and bone density in older hypogonadal men, but the drug is not a broad wellness therapy. The T-Trials investigators noted a numerically higher rate of cardiovascular events in the testosterone group (though not statistically significant at N=788), prompting ongoing cardiovascular outcome trials.

Transfer Risk: A Real-World Safety Problem Unique to AndroGel

Secondary testosterone exposure is a documented safety problem for AndroGel that does not exist with oral enclomiphene. The FDA added a Black Box Warning to all topical testosterone products in 2009, citing reports of virilization in children who had skin-to-skin contact with male users, including clitoral enlargement in a 2-year-old girl and accelerated pubic hair growth in a 9-month-old boy. Transfer risk is substantially reduced by washing hands after application, covering the application site with clothing, and showering before contact. Still, for men with young children or female partners who are pregnant, this Black Box Warning warrants explicit counseling.

Testosterone Levels and Hormonal Profiles Compared

Both drugs normalize total testosterone in most patients, but the hormonal fingerprint differs sharply.

| Parameter | Enclomiphene 25 mg/day | AndroGel 1% 5 g/day | |---|---|---| | Total T (typical) | 400 to 600 ng/dL | 400 to 700 ng/dL | | LH | Elevated (3 to 8 IU/L) | Suppressed (<1 IU/L) | | FSH | Elevated (3 to 6 IU/L) | Suppressed (<1 IU/L) | | Sperm concentration | Maintained or increased | Near-zero after 3 to 6 months | | Estradiol | May rise modestly | Rises proportionally with T | | Testicular volume | Stable | Decreases 20 to 30% over 12 months |

A pharmacokinetic study of enclomiphene published in Andrology confirmed that the drug produces a pulsatile LH surge pattern resembling physiologic secretion rather than the flat suppression profile seen with exogenous androgen therapy.

Symptom Relief: Which Drug Works Faster?

AndroGel works faster. Most men using AndroGel 1% report improvements in energy and libido within 3 to 6 weeks of reaching target T levels. Enclomiphene requires the hypothalamic-pituitary axis to respond, LH to rise, and Leydig cells to increase output. That chain typically takes 4 to 8 weeks to produce a stable T increase, with full symptom relief often not apparent until week 8 to 12. Kim et al. 2016 reported that mean total T reached above 400 ng/dL by week 4 in the 25 mg enclomiphene arm, but symptom questionnaire scores continued improving through week 12.

For a man with severe symptomatic hypogonadism (total T below 200 ng/dL, significant fatigue, depression, erectile dysfunction), the slower onset of enclomiphene may be clinically meaningful. AndroGel's faster, more predictable T normalization is an advantage in that scenario. For a man with borderline low T (250 to 350 ng/dL), intact testicular function, and fertility goals, the 4 to 8 week wait for enclomiphene is a reasonable trade-off.

Who Should Use Each Drug

Candidates for Enclomiphene Citrate

The clearest candidates for enclomiphene are men with secondary hypogonadism (low T with normal or low-normal LH/FSH) who meet one or more of these criteria:

• Active fertility plans or desire to preserve future fertility
• Age <45 with potentially reversible hypogonadism (obesity, sleep apnea, chronic stress, medications)
• Objection to topical application logistics or transfer risk
• Prior exogenous TRT with HPG axis suppression and desire to restart endogenous production

Obesity-related secondary hypogonadism, one of the most common patterns in clinical practice, may respond particularly well to enclomiphene because the underlying Leydig cell capacity is often intact but suppressed by hyperleptinemia and elevated estradiol from peripheral aromatization.

Candidates for AndroGel

AndroGel is appropriate when the goal is reliable, fast T normalization without fertility concerns. Specific populations include:

• Men with primary hypogonadism (elevated LH/FSH, damaged testes) where endogenous stimulation cannot work
• Men over 60 with symptomatic hypogonadism and low baseline LH (the T-Trials population)
• Men who have completed family building and prefer a well-studied, FDA-approved therapy
• Men who have not responded to 3 to 6 months of SERM-based therapy

The Endocrine Society guideline (2018) recommends testosterone therapy for men with "unequivocal symptomatic androgen deficiency" and advises shared decision-making for men with borderline T levels between 200 to 400 ng/dL.

Side-Effect Profiles Side by Side

Enclomiphene Side Effects

The most common adverse effects reported in enclomiphene trials are mild and transient: headache (approximately 10 to 15% of participants in Kim et al.), nausea, and visual disturbances. Because enclomiphene is the purified trans-isomer without accumulated zuclomiphene, the visual side-effect rate appears lower than with racemic clomiphene, though head-to-head tolerability data remain limited.

Estradiol may rise moderately because elevated LH drives more Leydig cell testosterone, which undergoes peripheral aromatization. Monitoring E2 at 6 to 12 weeks allows dose adjustment or low-dose aromatase inhibitor consideration if symptomatic. Polycythemia risk is lower with enclomiphene than with exogenous T because T levels rarely exceed the physiologic ceiling imposed by normal testicular feedback. A cross-sectional review in the Journal of Urology confirmed that hematocrit elevation is substantially less common with SERM-based therapy than with injectable or topical testosterone therapy.

AndroGel Side Effects

The most clinically significant adverse effects of AndroGel are polycythemia (hematocrit above 54%), acne, skin irritation at the application site, and the transfer risk already described. The T-Trials reported that hematocrit exceeded 54% in 5.9% of men in the testosterone arm versus 0.8% in the placebo arm. Dose reduction or temporary cessation is required when polycythemia is detected.

The cardiovascular question remains open. The TRAVERSE trial (N=5,204 men with pre-existing or high risk for cardiovascular disease, mean age 63) examined testosterone gel and found non-inferiority for major adverse cardiovascular events versus placebo, with a MACE rate of 7.0% in the testosterone group versus 7.3% placebo over a median 33 months, partially reassuring but not exonerating in younger or lower-risk men outside the trial population. Atrial fibrillation was numerically higher in the testosterone arm in TRAVERSE, a finding that warrants monitoring in men with existing cardiac disease.

Switching from Enclomiphene to AndroGel

Some men start on enclomiphene and later switch to AndroGel, either because they did not respond adequately or because fertility goals changed. The switch is straightforward from an endocrinology standpoint: stop enclomiphene, wait 5 to 7 days for clearance, then initiate AndroGel at the standard starting dose of 5 g/day with T measured at 14 days.

Clinicians should counsel patients that after switching, LH and FSH will suppress within weeks and sperm output will decline within 3 to 6 months. Men who switch and later want to restore fertility will typically require either stopping AndroGel and waiting 6 to 18 months for HPG axis recovery, or adding hCG and FSH-based regimens to stimulate spermatogenesis while maintaining T levels. A study in Fertility and Sterility found that mean time to sperm recovery after stopping exogenous testosterone was 3.4 months to reach 10 million/mL and up to 12 months to reach pre-treatment baseline.

The reverse switch (AndroGel to enclomiphene) is more complex. Men with prolonged exogenous TRT exposure often have significant HPG axis suppression. Enclomiphene depends on a functional hypothalamic-pituitary axis to work. A trial of 4 to 8 weeks off AndroGel (with symptom monitoring) before starting enclomiphene is usually needed to confirm whether LH and FSH can recover to levels sufficient for enclomiphene to act on.

The HealthRX clinical team uses the following stepwise decision framework when patients ask about switching:

Step 1. Confirm HPG axis type: measure LH, FSH, total T, and free T. Primary hypogonadism (LH/FSH elevated) is not amenable to enclomiphene at any dose.

Step 2. Clarify fertility intent explicitly. Any residual fertility desire routes toward SERM-based or hCG-based therapy, not exogenous T.

Step 3. Assess T severity. Total T persistently below 200 ng/dL with severe symptoms favors faster-acting AndroGel. Total T 250 to 400 ng/dL with mild-to-moderate symptoms allows time for an 8 to 12 week enclomiphene trial.

Step 4. Review comorbidities. Polycythemia vera, sleep apnea not yet treated, or active cardiovascular disease requiring workup should delay AndroGel initiation per Endocrine Society guidance.

Step 5. Re-check at 8 to 12 weeks. If enclomiphene has not raised T above 400 ng/dL or symptoms remain significant, reassess whether exogenous T is warranted.

Cost and Access

AndroGel 1% (brand) carries a retail price of approximately $350, $500/month without insurance. Generic testosterone gel 1% is widely available at $30, $80/month through most pharmacies. The FDA approved the first generic testosterone gel in 2012.

Enclomiphene has no FDA-approved indication for male hypogonadism, meaning it is prescribed off-label and is not covered by most insurance plans for this use. Compounded enclomiphene from 503B outsourcing facilities typically costs $50, $120/month. Brand-name enclomiphene products (such as Androxal, which was studied in Phase III trials but did not receive FDA approval for hypogonadism) are not currently commercially available in the United States.

Monitoring Protocols

Monitoring on Enclomiphene

• Baseline: total T, free T, LH, FSH, estradiol, CBC, PSA (men over 40), lipid panel
• Week 6 to 8: total T, LH, FSH, estradiol, symptoms reassessment
• Week 12: full repeat panel, semen analysis if fertility is a goal
• Annually: CBC, PSA, lipid panel, total T

The Endocrine Society's 2018 guideline recommends checking hematocrit at 3 to 6 months on any testosterone-normalizing therapy, including SERM-based approaches, then annually thereafter.

Monitoring on AndroGel

• Baseline: total T (morning), free T, LH, FSH, estradiol, CBC, PSA, lipid panel
• Day 14 after initiation: morning total T to confirm therapeutic range (400 to 700 ng/dL)
• Month 3: hematocrit, PSA, symptoms
• Month 6: full repeat panel
• Annually: hematocrit, PSA, lipid panel, DRE in men over 40

FDA labeling for AndroGel 1% requires withholding therapy if PSA rises more than 1.4 ng/mL above baseline within 12 months or total PSA exceeds 4.0 ng/mL, pending urologic evaluation.

Summary of Key Differences

| Feature | Enclomiphene Citrate | AndroGel 1% | |---|---|---| | FDA approval (male hypogonadism) | No (off-label) | Yes (since 2000) | | Route | Oral, once daily | Topical, once daily | | Onset to symptom relief | 8 to 12 weeks | 3 to 6 weeks | | Fertility impact | Preserved or improved | Suppressed | | Transfer risk | None | Black Box Warning | | Polycythemia risk | Low | Moderate (5 to 6% per T-Trials) | | HPG axis | Stimulated | Suppressed | | Reversibility | Fast (days to weeks) | Slow (months) | | Cost (approximate) | $50, $120/month compounded | $30, $80/month generic gel |